報價延遲最少15分鐘:2026/08/02 06:38 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
316.01 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
4.42/8.31
|
|
企業價值
34.43B
|
| 資產負債 |
|
每股賬面淨值
45.88
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
5.34B
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
